



PRESS RELEASE

## **Crucell and DSM Announce PER.C6<sup>®</sup> Licensing Agreement with Chiron for Monoclonal Antibody Production**

**Leiden/Sittard, The Netherlands, June 15, 2004** - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics announced today that Crucell has signed a PER.C6<sup>®</sup> research license agreement with Chiron Corporation. Chiron is a California-based biotechnology company with global Blood Testing, Vaccines and BioPharmaceuticals businesses. This license allows Chiron to research and preclinically develop its portfolio of recombinant monoclonal antibody products using Crucell's PER.C6<sup>®</sup> technology.

Under the terms of the agreement, Crucell and DSM Biologics will receive an upfront payment and annual maintenance fees. Further financial details were not disclosed.

### **About Crucell**

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6<sup>®</sup> technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6<sup>®</sup> technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and currently employs 180 people. Crucell is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit [www.crucell.com](http://www.crucell.com).

### **About DSM Biologics**

DSM Biologics, a business unit of the DSM Pharmaceutical Products business group, is one of the world's leading contract manufacturers of biopharmaceutical products, the latest generation of drugs, mainly on the basis of native molecules and produced with the help of cell cultures. The company is renowned for its experience in the use of a broad range of cell culture systems (microbial and mammalian) and its expertise in the field of purification techniques. Established in 1986, DSM Biologics currently employs about 450 people, who are based at the company's two sites, one in Groningen, the Netherlands (ca. 1,000 liters fermentor capacity and 6,000 m<sup>2</sup>) and one in Montreal, Quebec, Canada (ca. 6,500 liters fermentor capacity and presently 10,000 m<sup>2</sup>). DSM Biologics is a joint venture of DSM and SGF, a business



development company based in Montreal, holding a minority stake. For more information, please visit [www.dsmbiologics.com/](http://www.dsmbiologics.com/).

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States.

**For further information please contact:**

**Crucell N.V.**

Elizabeth Goodwin  
Director Investor Relations and  
Corporate Communications  
Tel. +31 (0)71 524 8718  
Fax.+31 (0)71 524 8935  
[e.goodwin@crucell.com](mailto:e.goodwin@crucell.com)

**DSM Biologics**

Marcel Lubben  
Business Manager Licensing  
Tel. + 31 (0)46 47 73343  
Fax. + 31 (0)46 47 73179  
[marcel-m.lubben@dsm.com](mailto:marcel-m.lubben@dsm.com)